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Introduction
Social phobia is a commonly occurring anxiety disor-
der often associated with serious role impairment
(1). Social anxiety disorder (SAD) can be classiﬁed
into two subtypes: ‘discrete’ or ‘speciﬁc’ and ‘gener-
alised’.
Generalised SAD, also known as generalised social
phobia, is deﬁned as a persistent fear of most social
or performance situations in which one is exposed to
unfamiliar people or to possible scrutiny by others
(2). In the ‘discrete’ or ‘speciﬁc’ subtype, the patients
usually have public-speaking fears only. Generalised
social phobia is more severe and disabling than other
social phobias. The annual prevalence of SAD is
7–8% and lifetime prevalence is 12–14% (1,3). Gener-
alised SAD represents two-thirds of social phobias
(4). Data from the United States (2001–2002) showed
that the mean age at onset of SAD was 15.1 years,
with a mean duration of 16.3 years (5). Furthermore,
individuals were at an increased risk if they were
Native American, young or of low income (5).
Individuals with SAD have a high risk of develop-
ing additional anxiety and mood disorders, including
suicidal behaviour (6). Additionally, SAD has an
adverse impact on other comorbid mental conditions
such as bipolar disorder, eating disorders, and
personality disorders (3). Independent of these
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SUMMARY
Background: Social anxiety disorder (SAD) is associated with substantial reduction
in health-related quality of life (HRQoL). Escitalopram has proven efﬁcacy in the
short-term treatment of SAD and prevention of relapse. Objectives: To determine
whether the clinical effects of treatment translated into HRQoL beneﬁts and to
investigate costs of SAD treatment. Methods: Data on HRQoL and resource util-
isation were collected in a previously published clinical trial of escitalopram in
relapse prevention. Among 517 patients, 371 responded to 12 weeks of open-
label treatment with escitalopram and were randomised to escitalopram or placebo
for 24 weeks. HRQoL was assessed using the short form (SF)-36 instrument and
SF-6D utilities (preference-based index scores for overall HRQoL) were calculated.
Costs were calculated for responders over the acute phase and for non-relapsed
patients over the continuation phase, applying UK unit costs. Results: Health-
related quality of life was signiﬁcantly improved after the acute phase when com-
pared with baseline. The SF-6D utility increased by 0.047 in responders
(p < 0.0001) and 0.021 in non-responders (p = 0.0005). Healthcare costs were
non-signiﬁcantly lower in acute phase than during prestudy phase (p = 0.0587
from NHS perspective), as were productivity costs (p = 0.1440). HRQoL at last visit
was lower in relapsed than non-relapsed patients. The difference in utility was
)0.026 (p = 0.0007). Healthcare and productivity costs were non-signiﬁcantly
lower in the escitalopram group than in the placebo group. Conclusions: Both
effective acute treatment of SAD and prevention of relapse with escitalopram are
associated with signiﬁcant HRQoL beneﬁts. Despite some limitations, the cost anal-
ysis suggests that savings in physician-visits and inpatient care may offset drug
acquisition costs.
What’s known
• Escitalopram is effective in the treatment of
patients with generalised social anxiety disorder
(SAD) and the prevention of relapse.
• Health-related quality of life is substantially
impaired in patients with SAD.
What’s new
• Acute treatment of SAD and prevention of
relapse with escitalopram have positive effects on
HRQOL.
• Drug acquisition costs associated with
escitalopram were offset by savings in physician-
visits and inpatient care in the studied sample.
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rimental effect on health-related quality of life
(HRQoL) (7). In addition to its burden on individu-
als, SAD places a substantial burden on health and
social services (8). A study among members of a
Health Maintenance Organisation based in the USA
found that the average number of outpatient visits
per year was higher by 2.5 in patients with general-
ised SAD and no comorbid psychopathology, com-
pared with those without psychiatric diagnosis (9).
Furthermore, subjects with generalised SAD missed a
greater percentage of work time than those with no
psychiatric diagnosis (2.83% vs. 1.82%).
Established treatments for SAD include cognitive
behaviour therapy and selective serotonin reuptake
inhibitors (SSRIs). A number of SSRIs, including
paroxetine, sertraline and ﬂuvoxamine, have been
found to be effective in the treatment of generalised
SAD, based on randomised, placebo-controlled, clini-
cal trials (10–14). Furthermore, randomised clinical
trials in maintenance treatment over 24 weeks
showed that paroxetine (SAD) or sertraline (general-
ised SAD) was associated with a signiﬁcant reduction
in risk of relapse, compared with placebo (15,16). In
addition, escitalopram (Cipralex
  Product Mono-
graph, H. Lundbeck AS, Copenhagen, Denmark,
2007), an SSRI with efﬁcacy comparable to paroxe-
tine and more favourable tolerability than paroxetine,
is indicated for SAD (17,18).
Montgomery et al. (19) reported the results of a
multinational randomised, placebo-controlled trial of
escitalopram for the prevention of relapse in general-
ised SAD. HRQoL and resource utilisation data were
collected in association with this trial. Based on the
collected data, a secondary analysis was performed to
investigate whether the clinical effect of treatment
was associated with HRQoL beneﬁts and resource
savings. Our overall aim was to ﬁll the gap in the
quantitative literature concerning the impact of
relapse and response to treatment on HRQoL and
costs in patients with generalised SAD. More speciﬁ-
cally, the analysis had three objectives: (i) to assess
the extent to which HRQoL and costs were inﬂu-
enced by response to acute treatment, (ii) to assess
the impact of relapse on HRQoL and (iii) to assess
the impact of long-term treatment with escitalopram
on HRQoL and costs.
Material and methods
Study design and previous ﬁndings
The design of the clinical trial on which this analysis
is based was described by Montgomery et al. (19). A
total of 571 patients with a primary diagnosis of gen-
eralised SAD (per Diagnostic and Statistical Manual
4th edition criteria) and Liebowitz Social Anxiety
Score (LSAS) ‡ 70 received 12 weeks of open-label
treatment with escitalopram. The initial dose of
10 mg⁄day could be increased to 20 mg⁄day if clini-
cally indicated. Of these patients, 372 responded to
open-label treatment and 371 were randomised in a
1 : 1 ratio, using a computer-generated block-ran-
domisation list, to receive double-blind treatment
with escitalopram (n = 190) at a ﬁxed dose of 10 or
20 mg, or placebo (n = 181). Escitalopram and pla-
cebo tablets were identical in smell and appearance,
and packed identically. Treatment was continued for
24 weeks unless the patient relapsed or was with-
drawn for other reasons. Response was deﬁned as a
Clinical Global Impression-Improvement (CGI-I)
score of one or two (20). Relapse was deﬁned as
either an increase in LSAS total score of ‡ 10 points
or withdrawal of the patient from the study because
of lack of efﬁcacy as judged by the investigator. The
study was conducted across 76 centres in nine Euro-
pean countries, Canada and South Africa from Janu-
ary 2001 to June 2002. Patients from all countries
were included in this analysis.
This study showed that the probability of relapse
was 2.8 times lower in patients randomised to escita-
lopram (22% vs. 50% on placebo, p < 0.001). It was
concluded that escitalopram is effective and well tol-
erated for long-term treatment of generalised SAD.
HRQoL assessments
Health-related quality of life was assessed using the
Medical Outcome Study Short Form (SF-36) (21).
This is a generic instrument providing eight domain
scores: Physical Functioning (PF), Role limitations
because of Physical problems (RP), Bodily Pain (BP),
General perception of Health (GH), Social Function-
ing (SF), Role limitations because of Emotional
problems (RE), Mental Health (MH) and Vitality
(VT). Item scores related to each domain are coded,
summed and scaled from zero (worst possible health
state) to 100 (best possible health state). A 10-point
difference on any domain score is generally accepted
as clinically relevant (22).
Patients completed the SF-36 questionnaire at ini-
tiation of the acute phase (baseline), the end of the
acute phase, and at 12 and 24 weeks after randomi-
sation. Patients who did not complete the study
attended an early discontinuation visit, at which the
SF-36 was administered.
Health state utilities
Health state utilities are preference-based index mea-
sures of well-being that can be used to estimate qual-
ity-adjusted life-years (QALYs) for use in economic
evaluations (23). Conventionally, a utility of one
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sents a health state considered equivalent to death.
QALYs are health outcome measures that combine
length and quality of life and are calculated by multi-
plying the utility given to a health state by the time
spent in that state.
Brazier and colleagues (24,25) derived a six-
dimensional health state classiﬁcation, called the SF-
6D, from the SF-36 for which a preference-based
scoring system has been developed. This system was
used to derive health state utilities, i.e. SF-6D scores,
from the SF-36 questionnaire.
Resource utilisation
A resource utilisation questionnaire, speciﬁcally
developed for the purpose of this study, was admin-
istered at 12-week intervals (i.e. at the same visits as
SF-36). In this questionnaire, SAD-related resources
used over the past 12 weeks were recorded, including
physician consultations (excluding consultations car-
ried out for the study), visits to other healthcare pro-
fessionals and social workers, and hospitalisations. In
addition, patients were asked for details of sick leave
days related to SAD occurring during the study or
the 12 weeks preceding baseline. Resources used after
relapse or withdrawals from the study were not
recorded. Cost estimates also included acquisition of
escitalopram. Counts of returned tablets were
recorded at all visits. These data were used to calcu-
late the cost of escitalopram during the acute phase
and over the two trimesters (12-week periods) of the
continuation phase.
Estimation of costs
Healthcare resources were valued using unit costs
prevailing during 2006 in the UK, from the perspec-
tive of the NHS and Personal Social Services (abbre-
viated as the NHS perspective below), and from the
perspective of society. Costs associated with non-
conventional medicine, such as consultations with
acupuncture specialists or chiropractors, were
accounted for from the societal perspective but not
from the NHS perspective. Table 1 shows unit costs
for key resource items. It was not necessary to dis-
count costs to present value as the timeframe of the
study was < 1 year.
Productivity costs were reported separately from
other costs. The cost of a lost work day was based
on mean gross UK daily earnings in 2006. A value of
£107.46 per sick leave day was applied (26).
As resources used after discontinuation of the
study treatment were not systematically collected,
cost estimates for each study trimester are based on
patients who completed the trimester. Therefore, this
analysis only reports costs in responders over the
acute phase and in non-relapsed patients over the
continuation phase.
Statistical analyses
Descriptive statistical analyses were performed. Mean
and standard deviations were calculated for all
HRQoL scores and costs by trimester (12-week per-
iod). HRQoL scores at the end of acute phase or dis-
continuation were compared between responders and
non-responders using t-tests. Similarly, HRQoL
scores were compared between patients who sub-
sequently relapsed and other patients who continued
to receive long-term treatment. Data from question-
naires completed at time of relapse were used for
patients who relapsed, and data collected at the end
of the continuation phase or at withdrawal were used
for the remaining patients. Analysis of covariance
was used to compare HRQoL scores at the end of
the continuation phase, at relapse or upon with-
drawal between the two treatment groups, adjusting
for scores at randomisation. This adjustment was
necessary as HRQoL at randomisation might differ
between patients who subsequently relapsed and
those who did not, eventhough all were in remission.
Paired t-tests were performed to compare costs
over the 12 weeks preceding baseline with costs over
the acute phase. In addition, cost measurements were
compared between the escitalopram and placebo
patients for each trimester of the continuation phase
using t-tests. Healthcare costs were estimated with
and without the inclusion of hospitalisations as a
small number of costly hospitalisations introduced
substantial variability around overall cost estimates.
A level of signiﬁcance of 5% was used in interpret-
ing results of statistical tests. The hypothesis of
Table 1 Unit costs (GBP £2006) for key resource items
Resource Unit cost Reference
Escitalopram
28 Tablets, 10 mg £14.91 BNF (35)
28 Tablets, 20 mg £25.20
GP visit £25.00 PSSRU (36)
Psychiatrist consultation (20 min) £82.00 PSSRU (36)
Psychologist consultation (60 min) £66.00 PSSRU (36)
Nurse visit £23.50 PSSRU (36)
Social worker visit (30 min) £60.00 PSSRU (36)
Hospitalisation
Psychiatric ward (per day) £294.00 PSSRU (36)
Other ward (per day) £421.00 National
Reference
Costs (37)
GP, General Practitioner.
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patients or between two visits was rejected when
there was a p-value under 0.00625 for at least one
SF-36 domain score, based on the Bonferroni
method. All analyses were performed using SAS ver-
sion 9.1 (SAS Institute Inc., Cary, NC).
Results
The numbers of patients at different stages of the
study are shown in Figure 1. Completion rates for
the SF-36 questionnaire were relatively high through-
out the study for patients who had not withdrawn.
All but 10 patients completed the SF-36 question-
naire at baseline. However, the completion rates were
lower among patients who discontinued during the
ﬁrst half of the continuation phase. The question-
naire was completed at the time of discontinuation
by 76% of the 169 patients who attended an early
discontinuation visit over the whole continuation
phase. Among 133 patients who relapsed, 124 (93%)
completed the HRQoL assessment.
Acute phase
Short form-36 domain scores at baseline and at the
end of acute phase are shown in Figure 2, for
responders and for patients who did not respond to
treatment or discontinued within 12 weeks (desig-
nated as ‘non-responders’ below). For the respond-
ers, scores at the end of acute phase were
signiﬁcantly higher than at baseline for all domains
except PF (0.00625 signiﬁcance level). For non-
responders, baseline scores were comparable,
although slightly lower to those among responders
and statistically signiﬁcant improvements were
observed in three domains: GH, SF and MH. No sta-
tistically signiﬁcant decrease in any SF-36 domain
score occurred for non-responders. SF-6D utility
scores increased from 0.664 to 0.711 among respond-
ers and from 0.645 to 0.672 among non-responders.
Mean improvements in SF-6D utility adjusted on
baseline utility value were 0.049 [95% conﬁdence
interval (CI): 0.043–0.055; p < 0.0001] for respond-
ers and 0.018 (95% CI: 0.006–0.029; p = 0.0022) for
non-responders.
Table 2 shows costs over the acute phase com-
pared with those incurred over the 12 weeks preced-
ing the study. Estimated costs were relatively similar
from the NHS and the societal perspectives, as
healthcare expenditures not included in the NHS
perspective accounted for only 5–6% of the societal
costs. Nonetheless, the t-tests comparing costs
between prestudy and acute phases lead to different
interpretations according to the perspective. From
the societal perspective, estimated costs were signiﬁ-
cantly lower in the acute phase compared with those
in prestudy phase (p = 0.0410). From the NHS per-
spective, the difference between periods was negative
Figure 1 Flow chart summarising number and status of patients participating to the study by treatment arm and trimester
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analyses in Figure 3 suggest that hospitalisations
account for a substantial part of the difference
between the two periods. NHS costs were very simi-
lar when hospitalisation costs were excluded (mean
difference: )£4.36; p = 0.6877).
There was substantial variability in the cost of lost
workdays because many patients took no time off
work and a few patients were absent over long peri-
ods (sometimes, entire trimesters). 68% of patients
were in paid employment or self-employed. The
mean number of workdays lost decreased from 2.54
over the prestudy phase to 1.96 over the acute phase
among responders; this difference was not statistically
signiﬁcant (p = 0.1440).
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Figure 2 Short form-36 scores at baseline and end of acute phase. PF, Physical Functioning; RP, Role limitations because
of Physical problems; BP, Bodily Pain; GH, General perception of Health; SF, Social Functioning; RE, Role limitations
because of Emotional problems; MH, Mental Health; VT, Vitality. Numbers of patients at baseline: 366 responders, 141
non-responders; at end of acute phase: 363 responders, 107 non-responders
Table 2 Costs (GBP £2006) in responders over prestudy and acute phases
Prestudy Acute phase t-test
n mean (SD) n mean (SD) p-value
Total cost, NHS perspective
Including hospitalisations 371 183.32 (640.40) 371 118.82 (183.15) 0.0587
Excluding hospitalisations 371 115.24 (202.70) 371 110.88 (127.27) 0.6877
Total cost, societal perspective 371 196.01 (649.62) 371 125.29 (189.71) 0.0410
Productivity cost 370 273.01 (1385.70) 371 210.58 (1281.39) 0.1440
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Figure 3 Breakdown of costs (GBP £2006) from a NHS
perspective over prestudy and acute phases
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Short form-36 scores 24 weeks after randomisation
or at last visit, displayed in Table 3, showed that
patients who did not relapse reported a better
HRQoL than those who did relapse. Signiﬁcantly
higher scores were observed among non-relapsed
patients on the four domains more related to MH,
with particularly large differences in the social-func-
tioning and role-emotional dimensions. Scores on
the physical domains (PF, RP, BP and GH) seemed
to be little affected by relapse. The SF-6D utility in
non-relapsed patients exceeded the utility in patients
who relapsed by 0.026 (p = 0.0007).
Health-related quality of life scores at the last
assessment visit were similar to those at randomisa-
tion among patients who received long-term treat-
ment with escitalopram (see Table 4). However, for
patients randomised to placebo, several mean
domain scores decreased signiﬁcantly from randomi-
sation to the end of the continuation phase or last
visit: SF (mean difference: )7.16; p < 0.0001), RE
()7.80; p = 0.0029) and MH ()6.92; p < 0.0001).
Differences in SF-36 scores at last visit between treat-
ment groups, adjusted for scores at randomisation,
were statistically signiﬁcant at the 0.00625 level for
the SF and MH dimensions, in favour of continuing
treatment with escitalopram. In addition, the SF-6D
estimate at last assessment was higher by 0.018 in the
escitalopram arm (p = 0.0087).
For those patients who had not relapsed and
completed the SF-36 questionnaire 12 weeks after
randomisation (halfway through continuation
phase), all mean domain scores were higher in the
escitalopram arm, but no difference reached the
0.00625 signiﬁcance level. The SF domain score was
higher by 6.93 in the escitalopram arm
(p = 0.0194), the RE domain score by 10.15
(p = 0.0153) and the MH domain score by 6.29
(p = 0.0072); other differences were smaller. The
overall difference in SF-6D utility at 12 weeks after
randomisation was not statistically signiﬁcant (mean
difference: 0.012; p = 0.1942).
Table 3 Short form-36 and -6D scores at last
assessment
No relapse
(n = 227),
mean (SD)
Relapse
(n = 124),
mean (SD) Difference p-value
PF 94.4 (11.9) 95.0 (9.9) 0.55 0.6443
RP 87.1 (28.4) 85.5 (29.6) )1.63 0.6123
BP 83.6 (20.4) 79.9 (23.7) )3.66 0.1306
GH 77.5 (17.3) 74.6 (19.4) )2.86 0.1584
VT 65.0 (17.3) 58.2 (17.9) )6.86 0.0005
SF 80.2 (19.9) 64.5 (27.3) )15.72 < 0.0001
RE 85.8 (27.7) 71.0 (38.5) )14.79 0.0002
MH 73.8 (16.7) 65.8 (18.6) )7.98 < 0.0001
SF-6D 0.718 (0.068) 0.691 (0.071) )0.026 0.0007
PF, Physical Functioning; RP, Role limitations because of Physi-
cal problems; BP, Bodily Pain; GH, General perception of
Health; SF, Social Functioning; RE, Role limitations because of
Emotional problems; MH, Mental Health; VT, Vitality.
Table 4 Short form-36 and -6D scores at randomisation and last visit, by treatment group
Control Escitalopram
Adjusted.
difference* p-value
Randomisation
(n = 179),
mean (SD)
Last
assessment
(n = 173),
mean (SD)
Randomisation
(n = 184),
mean (SD)
Last
assessment
(n = 178),
mean (SD)
PF 92.5 (15.1) 93.6 (10.7) 94.7 (9.8) 94.7 (12.3) )0.55 0.5758
RP 86.6 (27.1) 83.6 (30.5) 89.9 (23.1) 89.5 (25.0) 2.74 0.3603
BP 80.1 (22.2) 80.5 (22.4) 85.1 (18.7) 83.8 (20.5) )0.77 0.7069
GH 77.4 (17.3) 75.5 (18.9) 78.6 (18.0) 77.2 (17.2) )1.26 0.3622
VT 63.0 (17.3) 60.4 (17.6) 64.4 (15.9) 63.8 (17.9) )3.14 0.0640
SF 77.2 (21.1) 70.9 (24.7) 76.6 (20.3) 78.7 (22.5) )9.70 < 0.0001
RE 84.0 (29.2) 74.2 (35.6) 84.1 (29.3) 84.7 (29.2) )7.69 0.0167
MH 74.8 (14.8) 68.3 (17.2) 74.2 (16.3) 73.1 (18.1) )6.48 < 0.0001
SF-6D 0.711 (0.064) 0.698 (0.066) 0.712 (0.064) 0.715 (0.075) )0.018 0.0087
*Difference in scores at last assessment between treatment groups, adjusted on value at randomisation. PF, Physical Functioning;
RP, Role limitations because of Physical problems; BP, Bodily Pain; GH, General perception of Health; SF, Social Functioning;
RE, Role limitations because of Emotional problems; MH, Mental Health; VT, Vitality.
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non-signiﬁcantly lower in the escitalopram group
than in the placebo group over the two trimesters of
the continuation phase, from the NHS and societal
perspectives (see Table 5). As noted for the acute
phase, differences between the arms appeared to be
largely precipitated by hospitalisation costs (see Fig-
ure 4), which occurred in very few patients and
introduced substantial uncertainty around estimates
of total costs. Similarly, productivity costs were lower
in the escitalopram arm over the two trimesters, but
the variability in these costs was substantial and dif-
ferences between treatment arms were not statistically
signiﬁcant.
Estimates of productivity costs were lower over
each trimester of the randomisation phase than over
the open-label phase across the two treatment arms
(see Tables 2 and 5). However, the corresponding
differences were not statistically signiﬁcant
(p = 0.1454 for trimester 2 vs. open-label and
p = 0.6488 for trimester 3 vs. open-label).
Discussion
This study examined HRQoL and healthcare costs in
patients with SAD treated with escitalopram over 12
or 36 weeks. One of the ﬁndings of this study was
that HRQoL, as measured by the SF-36 instrument,
was improved after 12 weeks of treatment with escit-
alopram. Unsurprisingly, the improvement was
greater for treatment responders [i.e. those with a
CGI-I of one or two (19)] than non-responders, with
differences on SF-36 MH dimensions of between 10
and 30 points, which was greater than the accepted
clinically relevant 10-point difference (22). Respond-
ers HRQoL subscale scores returned to levels compa-
rable to that of population norms (21). However, the
difference between scores at baseline and after acute
open-label treatment was statistically signiﬁcant even
for non-responders. Differences in SF and role emo-
tional domain scores were the largest. Furthermore,
relapse between 12 and 36 weeks was found to have
a negative impact on HRQoL, as shown by the
Table 5 Costs (GBP £2006) by treatment group and trimester over continuation phase, in the absence of relapse
Trimester 2 Trimester 3
Placebo
(n = 96)
Escitalopram
(n = 145) p-value
Placebo
(n = 79)
Escitalopram
(n = 123) p-value*
Total cost, NHS perspective, including hospitalisations 180.20 110.53 0.3877 201.74 124.32 0.4431
Total cost, NHS perspective, excluding hospitalisations 110.03 104.73 0.8910 84.50 110.63 0.3511
Total cost, social perspective, including hospitalisations 183.38 115.70 0.4093 206.56 129.67 0.4468
Productivity cost 144.40 115.61 0.8163 186.35 149.40 0.8091
*Student’s t-test.
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Figure 4 Breakdown of costs (GBP £2006) from NHS perspective over acute and continuation phases, by treatment group
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non-relapsed patients. Also, the SF-36 dimensions
primarily affected by relapse were SF and role emo-
tional. In addition, HRQoL was signiﬁcantly better
in the escitalopram group than in the placebo group
at end of continuation phase on two dimensions (SF
and MH) and in terms of overall utility, as could be
expected given the lower probability of relapse
among patients continuing escitalopram beyond
12 weeks. A trend towards higher HRQoL subscale
scores and overall utility in the escitalopram group
was observed halfway though the continuation phase
among non-relapsed patients, suggesting that relapse
might not capture the entire effect of escitalopram
on HRQoL.
Quantitatively, the results suggested that the effect
of escitalopram on HRQoL was somewhat more
modest in patients with generalised SAD than in
those with generalised anxiety disorder (GAD). A
study of escitalopram using a similar design among
patients with GAD had shown that the SF-6D score
increased from 0.64 at baseline to 0.77 at the end of
the open-label period (compared with an increase
from 0.66 to 0.71 in responders only in this study).
Furthermore, in the GAD study, the decrement in
SF-6D utility associated with relapse was 0.06 (com-
pared with 0.03 in SAD).
Total healthcare costs were signiﬁcantly lower over
the acute phase than over the 12 weeks preceding the
study from the societal perspective (p = 0.0410). This
suggested that the acquisition cost of escitalopram
was more than offset by savings in physician-visits
and inpatient care. However, the difference in costs
between the prestudy and acute phases was not sta-
tistically signiﬁcant from the NHS perspective
(p = 0.0587), although costs from the NHS perspec-
tive were close to those from the societal perspective.
Furthermore, when hospitalisation costs were
excluded, healthcare costs were very similar between
the two periods. Likewise, productivity costs were
not signiﬁcantly different between the prestudy and
acute phases. The comparison of healthcare costs
between the acute and continuation phases suggests
that costs increased among non-relapsed patients in
the placebo arm but not in the escitalopram arm.
However, healthcare costs in non-relapsed patients
were not signiﬁcantly different between treatment
arms, neither from NHS perspective nor from socie-
tal perspective. Similarly, a non-signiﬁcant trend
towards lower productivity costs in the escitalopram
arm, compared with the placebo arm, was found
over the continuation phase.
This study has several limitations, especially con-
cerning the evaluation of the extent to which costs
are inﬂuenced by response to treatment. The com-
parison of costs during the acute phase with costs
prior to baseline should be interpreted with caution,
as study-related visits occurring over the acute phase
were not counted, although a proportion of them
might have occurred independently of the study.
This might account for a part of the difference in
societal costs between the prestudy and acute phases,
as the difference in costs of physician-visits repre-
sented 73% of the difference in societal costs. Thus,
if costs of physician-visits were not counted, the total
costs in the prestudy and acute phases would be
roughly similar, although still slightly lower in the
acute phase. Furthermore, the difference in hospitali-
sation costs, which represented 85% of the difference
in total healthcare costs from the societal perspective,
is subject to uncertainty. Only 10 patients were hos-
pitalised in the prestudy phase and two in the acute
phase (among patients included in the cost analysis).
However, the hypothesis that effective treatment is
associated with a reduction in hospitalisation costs
does seem plausible, as anxiety disorders are known
to cause hospitalisations (psychiatric or non-psychi-
atric) (27). Compared with other anxiety disorders,
hospitalisation may be less frequent in SAD as suffer-
ers are understandably frightened by the phobic situ-
ations expected in hospital. One study compared use
of medical resources between panic disorder and
social phobia; hospitalisation rates were similar for
both (around 10%) but admission to emergency
department was higher for panic disorder patients
(21% vs. 7%) (28). It would have been desirable to
assess the extent to which costs are inﬂuenced by
response to treatment by comparing costs in
responders and non-responders. However, the avail-
able data did not allow for such a comparison. Also,
the analysis presented here, comparing costs before
and after treatment in responders, relies on the
assumption that costs would remain constant from
one trimester to the next in the absence of symptom-
atic improvement.
Costs were estimated by applying unit prices pre-
vailing in the UK for patients from all countries par-
ticipating in the trial. Among 371 patients who were
included in the analysis for the continuation phase,
35 were from the UK. The comparison of costs
between treatment groups assumes that there was no
interaction between treatment and country on
resource utilisation. This assumption has been made
in a number of other economic evaluations (29).
However, the impact of treatment on resource use
may differ among the countries. For example, even if
the effect of treatment on the number of physician-
visits may be comparable between countries, the
effect on the number of psychiatrist consultations is
likely to be relatively small in the UK. This could
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its are more expensive than general practitioner (GP)
visits. This problem may have also affected the com-
parison between prestudy and acute phases. Never-
theless, the cost estimates obtained here are in line
with results of a previous study by Patel et al. (8) of
the economic consequences of social phobia. He esti-
mated the annual healthcare costs of social phobia at
£609 in 1997⁄1998 prices, which corresponds to
approximately £180 per trimester in 2006 prices. This
value is very close to our estimate of £183 per tri-
mester for total healthcare costs from the NHS and
PSS perspective over the prestudy phase.
It was not possible to distinguish between cases
that did not use any resource during a trimester and
cases where resource use was not reported. This
might have led to an underestimation of costs, irre-
spective of treatment group or period. However, the
extent of this underestimation would have been rela-
tively small if completion rates for the resource util-
isation questionnaire were comparable to those for
the SF-36 questionnaire. Approximately 95% of
patients completed the SF-36 at end of the study or
after discontinuation, irrespective of treatment group
or presence of relapse. Although approximately one-
quarter of those who discontinued did not complete
the HRQoL assessment at the time of discontinuing
the study treatment, SF-36 data were collected at a
later visit in most of these cases.
This study compared costs and HRQoL between
treatment groups, but no cost-effectiveness analysis
(CEA) was actually performed. The comparison of
costs between treatment groups was restricted to
non-relapsed patients. Relapses are likely to generate
costs as a new therapy will be initiated in many cases
and physician-visits will occur at shorter intervals
following initiation of new therapy. For example,
according to guidelines of the National Institute for
Health and Clinical Excellence for the management
of GAD in the UK, efﬁcacy and side effects should
be reviewed at 2, 4, 6 and 12 weeks following pre-
scription of a new therapy, and subsequently at 8- to
12-week intervals (30). In order to perform a full
economic evaluation of escitalopram in the preven-
tion of SAD, it would be necessary to account for
the savings realised because of relapses avoided.
Although no CEA was performed in this study,
the study provides data that could be useful for
future economic evaluations of treatment of SAD, in
particular health state utilities. The utility improve-
ment associated with response was estimated at 0.047
(95% CI: 0.040–0.055), by comparison with baseline
value, or 0.040 (95% CI: 0.026–0.054) by comparison
with the value in non-responders. Furthermore, the
utility decrement associated with relapse was )0.026
(95% CI: )0.042 to )0.011). These are probably con-
servative estimates, as they are based on the SF-6D
instrument. The SF-6D utility index has a smaller
range than the EQ-5D, another widely used generic
HRQoL instrument providing health state utilities.
Also, differences in utility between health states based
on SF-6D are often smaller than the differences based
on the EQ-5D (31,32).
The literature relating to HRQoL in SAD is not
very abundant, but some previous studies have
shown that SAD is associated with a marked reduc-
tion in HRQoL, for example Stein et al. (33), who
used the Quality of Well Being Scale and Simon
et al. (7), who used the SF-36. Simon et al. reported
scores of 59.4 for VT, 65.9 for SF, 67.9 for emotional
role and 58.5 for MH, based on 33 patients with
SAD. Baseline scores in our sample were below the
scores reported by Simon et al., especially the social
function score (49.3 on average across responders
and non-responders). Thus, our study supports pre-
vious evidence indicating that patients with SAD are
substantially impaired in their quality of life. The
results presented here are consistent with the conclu-
sions of a recent meta-analysis on quality of life in
anxiety disorders (34). This meta-analysis demon-
strated that the HRQoL impairment of SAD was less
multidimensional than that of other anxiety disor-
ders, and more concentrated on the social domain.
The quality of life related to physical health was not
signiﬁcantly lower for patients with SAD than for
non-clinical controls, whereas a signiﬁcant difference
was found for other disorders. In this study, relapse
and treatment were signiﬁcantly associated with
dimensions such as SF and MH, but not with physi-
cal dimensions of HRQoL. Unfortunately, this is the
only study to our knowledge investigating the impact
of treatment on HRQoL, thus no reference is avail-
able for comparison.
In conclusion, changes in the severity of SAD
translate into changes in overall HRQoL. Patients
with SAD responding to acute treatment report
improved HRQoL, and those who subsequently
relapse have reduced scores. Furthermore, long-term
treatment with escitalopram, which is effective in
preventing relapse, is associated with a signiﬁcant
beneﬁt in terms of HRQoL. The evidence for treat-
ment-related changes in healthcare costs is limited,
but suggests that additional drug acquisition costs
may be offset by reductions in costs because of phy-
sician-visits and hospitalisation.
Authors’ contribution
Study conception and design: Montgomery, Francois
and Auquier. Acquisition of data: Montgomery.
Escitalopram for relapse prevention in patients with generalised SAD 1701
ª 2008 The Authors
Journal compilation ª 2008 Blackwell Publishing Ltd Int J Clin Pract, November 2008, 62, 11, 1693–1702Analysis and interpretation of data: Aballe ´a, Roı ¨z,
Francois, Despiegel and Montgomery. Drafting of
manuscript: Aballe ´a, Despiegel and Francois. Critical
revision: Franc ¸ois, Montgomery, Despiegel and Aba-
lle ´a, Roı ¨z and Auquier.
Acknowledgements
This analysis was carried out by i3 Innovus under a
grant from Lundbeck A⁄S. Lundbeck A⁄S provided
the raw data and reviewed article drafts; i3 Innovus
carried out analyses and interpreted data and results
independently.
References
1 Sareen L, Stein M. A review of the epidemiology and approaches
to the treatment of social anxiety disorder. Drugs 2000; 59: 497–
509.
2 American Psychiatric Association. Diagnostic and Statistical Manual
of Mental Disorders. 4th edn, Text Revision (DSM-IV-TR). Arling-
ton, VA: American Psychiatric Association, 2000.
3 Stein MB. An epidemiologic perspective on social anxiety disorder.
J Clin Psychiatry 2006; 67 (Suppl. 12): 3–8.
4 Kessler RC, Stein MB, Berglund P. Social phobia subtypes in the
National Comorbidity Survey. Am J Psychiatry 1998; 155: 613–9.
5 Grant BF, Hasin DS, Blanco C et al. The epidemiology of social
anxiety disorder in the United States: results from the National Ep-
idemiologic Survey on alcohol and related conditions. J Clin Psy-
chiatry 2005; 66: 1351–61.
6 Culpepper L. Social anxiety disorder in the primary care setting. J
Clin Psychiatry 2006; 67 (Suppl. 12): 31–7.
7 Simon NM, Otto MW, Korbly NB, Peters PM, Nicolaou DC, Pol-
lack MH. Quality of life in social anxiety disorder compared with
panic disorder and the general population. Psychiatr Serv 2002; 53:
714–8.
8 Patel A, Knapp M, Henderson J, Baldwin D. The economic conse-
quences of social phobia. J Affect Disord 2002; 68: 221–33.
9 Katzelnick DJ, Kobak KA, DeLeire T et al. Impact of generalized
social anxiety disorder in managed care. Am J Psychiatry 2001;
158: 1999–2007.
10 Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Ger-
gel I. Paroxetine treatment of generalized social phobia (social anx-
iety disorder): a randomized controlled trial. JAMA 1998; 280:
708–13.
11 Van Ameringen MA, Lane RM, Walker JR et al. Sertraline treat-
ment of generalized social phobia: a 20-week, double-blind, pla-
cebo-controlled study. Am J Psychiatry 2001; 158: 275–81.
12 Blomhoff S, Haug TT, Hellstrom K et al. Randomised controlled
general practice trial of sertraline, exposure therapy and combined
treatment in generalised social phobia. Br J Psychiatry 2001; 179:
23–30.
13 van Vliet IM, den Boer JA, Westenberg HG. Psychopharmacological
treatment of social phobia; a double blind placebo controlled study
with ﬂuvoxamine. Psychopharmacology (Berl) 1994; 115: 128–34.
14 Stein MB, Fyer AJ, Davidson JR, Pollack MH, Wiita B. Fluvox-
amine treatment of social phobia (social anxiety disorder): a dou-
ble-blind, placebo-controlled study. Am J Psychiatry 1999; 156:
756–60.
15 Stein DJ, Versiani M, Hair T, Kumar R. Efﬁcacy of paroxetine for
relapse prevention in social anxiety disorder: a 24-week study. Arch
Gen Psychiatry 2002; 59: 1111–8.
16 Walker JR, Van Ameringen MA, Swinson R et al. Prevention of
relapse in generalized social phobia: results of a 24-week study in
responders to 20 weeks of sertraline treatment. J Clin Psychophar-
macol 2000; 20: 636–44.
17 Dhillon S, Scott LJ, Plosker GL. Escitalopram: a review of its use in
the management of anxiety disorders. CNS Drugs 2006; 20: 763–90.
18 Ipser JC, Kariuki CM, Stein DJ. Pharmacotherapy for social anxi-
ety disorder: a systematic review. Expert Rev Neurother 2008; 8:
235–57.
19 Montgomery SA, Nil R, Durr-Pal N, Loft H, Boulenger JP. A 24-
week randomized, double-blind, placebo-controlled study of escita-
lopram for the prevention of generalized social anxiety disorder.
J Clin Psychiatry 2005; 66: 1270–8.
20 Guy W, Bonato RR. Manual for the ECDEU Assessment Battery,
2nd revised edn. Chevy Chase, MD: National Institute of Mental
Health [12-1-12-6], 1970.
21 Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health
survey (SF-36). I. Conceptual framework and item selection. Med
Care 1992; 30: 473–83.
22 Ware JE. SF-36 Physical and Mental Health Summary Scales: a
User’s Manual. Boston, MA: The Health Institute, New England
Medical Center, 1994.
23 Coons SJ, Rao S, Keininger DL, Hays RD. A comparative review of
generic quality-of-life instruments. Pharmacoeconomics 2000; 17:
13–35.
24 Brazier J, Roberts J, Deverill M. The estimation of a preference-
based measure of health from the SF-36. J Health Econ 2002; 21:
271–92.
25 Brazier JE, Roberts J. The estimation of a preference-based mea-
sure of health from the SF-12. Med Care 2004; 42: 851–9.
26 Ofﬁce for National Statistics. Annual Survey of Hours and Earnings,
2006. http://www.statistics.gov.uk (accessed 12 August 2008).
27 Lepine JP. The epidemiology of anxiety disorders: prevalence and
societal costs. J Clin Psychiatry 2002; 63 (Suppl. 14): 4–8.
28 Swinson RP, Cox BJ, Woszczyna CB. Use of medical services and
treatment for panic disorder with agoraphobia and for social pho-
bia. CMAJ 1992; 147: 878–83.
29 Barbieri M, Drummond M, Willke R, Chancellor J, Jolain B,
Towse A. Variability of cost-effectiveness estimates for pharmaceu-
ticals in Western Europe: lessons for inferring generalizability.
Value Health 2005; 8: 10–23.
30 National Institute of Health and Clinical Excellence. Clinical
Guideline 22. Anxiety: Management of Anxiety (Panic Disorder,
with or without Agoraphobia, and Generalised Anxiety Disorder)
in Adults in Primary, Secondary and Community Care, 2004
December. http://www.nice.org.uk/CG022NICEguideline (accessed
22 July 2007).
31 Brazier J, Roberts J, Tsuchiya A, Busschbach J. A comparison of
the EQ-5D and SF-6D across seven patient groups. Health Econ
2004; 13: 873–84.
32 Petrou S, Hockley C. An investigation into the empirical validity
of the EQ-5D and SF-6D based on hypothetical preferences in a
general population. Health Econ 2005; 14: 1169–89.
33 Stein MB, Roy-Byrne PP, Craske MG et al. Functional impact and
health utility of anxiety disorders in primary care outpatients. Med
Care 2005; 43: 1164–70.
34 Olatunji BO, Cisler JM, Tolin DF. Quality of life in the anxiety dis-
orders: a meta-analytic review. Clin Psychol Rev 2007; 27: 572–81.
35 British National Formulary. http://www.bnf.org/bnf/ (accessed 12
August 2008).
36 Curtis L, Netten A. Unit Costs of Health and Social Care. Kent:
University of Kent, 2006.
37 Department of Health. NHS Reference Costs, 2006. http://
www.dh.gov.uk (accessed 3 May 2007).
Paper received March 2008, accepted July 2008
1702 Escitalopram for relapse prevention in patients with generalised SAD
ª 2008 The Authors
Journal compilation ª 2008 Blackwell Publishing Ltd Int J Clin Pract, November 2008, 62, 11, 1693–1702